Evaluating Sentinel Lymph Node Biopsy for Ocular Surface and Eyelid Cancers

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study focuses on patients diagnosed with various malignant ocular surface and adnexal tumors, including sebaceous carcinoma and Merkel cell carcinoma. Participants will undergo a series of evaluations, including staging, imaging, and sentinel lymph node biopsy, to assess the presence of cancer spread. The study spans nine years, with patient enrollment for three years and a five-year follow-up period to evaluate survival outcomes. Data will be analyzed at multiple time points to confirm findings and improve treatment strategies.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* All patients with Porocarcinoma, Ca of Merkel, Ca Sebaceous
* Patients with cutaneous adnexal melanoma with thickness ≥1.5 mm, Clark's level ≥3, \>1 mitotic figure per high-power field.
* Patients with conjunctival melanoma both primary and recurrent and associated with primary acquired melanosis with atypia.
* Patients with squamous cell Ca of adnexa with Staging ≥3, locally recurrent or with perineural invasion
* Patients with squamous cell Ca of the surface with Staging ≥3 and/or multicenter
* Signature of informed consent to participate in the study
* cNo

Exclusion Criteria:

* Age less than 18 years
* Patients with metastatic disease at diagnosis
* All patients who do not fit the inclusion criteria
* Failure to obtain informed consent

Where it's running

• Gustavo Savino
  Roma, Rome, Italy Recruiting

Study contacts

• Study coordinator: Gustavo Savino, MD
• Email: oncologiaoculare@policlinicogemelli.it
• Phone: 0630154528

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Surgical removal of eye-surface squamous tumors in people living with HIV in Sub-Saharan Africa

  We will try surgical removal of suspected eye-surface squamous tumors in people living with HIV in sub‑Saharan Africa and follow them for 12 months to see how surgery, tissue testing, and follow-up care work.

  Recruiting AIDS Malignancy Consortium · Kampala · NCT04704648

• Lifileucel (TIL) plus chemotherapy and IL-2 for advanced cutaneous squamous cell and Merkel cell carcinoma

  This trial will try lifileucel (tumor-infiltrating lymphocytes) combined with lymphodepleting chemotherapy and interleukin-2 in adults with unresectable or metastatic cutaneous squamous cell carcinoma or Merkel cell carcinoma who have previously received immunotherapy.

  Recruiting Phase 2 Dana-Farber Cancer Institute · Boston, Massachusetts · NCT07288073

• In-home cancer treatment with remote specialist support for patients in the Florida Panhandle

  This program will try giving standard cancer treatments at home to people living in the Florida Panhandle and nearby areas to see if they prefer it and have better treatment satisfaction.

  Recruiting Phase 2 Mayo Clinic · Jacksonville, Florida · NCT07285044

• Testing AZD6750 safety in adults with selected advanced or metastatic solid tumors

  This trial tests whether AZD6750, a CD8-guided IL-2 medicine given alone or with other cancer drugs, is safe and how it behaves in adults with certain advanced or metastatic solid tumors.

  Recruiting at 13 sites Phase 1/2 AstraZeneca · Grand Rapids, Michigan and 12 other locations · NCT07115043

• Phase I testing of 225Ac-ETN029 for advanced DLL3-positive tumors

  This trial will test 225Ac-ETN029, with 111In-ETN029 used for imaging, to see if the treatment is safe, tolerable, and shows early anti-tumor activity in adults with advanced DLL3-positive neuroendocrine cancers.

  Recruiting at 8 sites Phase 1 Novartis · Iowa City, Iowa and 7 other locations · NCT07006727

• Radiation plus tarlatamab for DLL3-expressing tumors

  This trial will test whether giving tarlatamab together with standard palliative or consolidative radiation is safe for adults with DLL3-expressing or DLL3-prevalent tumors such as melanoma, medullary thyroid cancer, sinonasal undifferentiated carcinoma, esthesioneuroblastoma, and bladder cancer.

  Recruiting at 3 sites Phase 1/2 University of Arizona · Gilbert, Arizona and 2 other locations · NCT06814496

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.